Search

Your search keyword '"Matsuda, Tamotsu"' showing total 472 results
Start Over Author "Matsuda, Tamotsu"
472 results on '"Matsuda, Tamotsu"'

1. The Differences Between Bowing as Among Adult Members of Society in Japan and the Bowing of Japanese Students

Author

Okado, Kohei, Hamada, Hiroyuki, Kida, Noriyuki, Matsuda, Tamotsu, Ohashi, Rie, Kitamura, Kazuki, Smith, Andy, Todisco, David, Jackson, Luke, Ogimoto, Tatsuya, Kacprzyk, Janusz, Series Editor, Pal, Nikhil R., Advisory Editor, Bello Perez, Rafael, Advisory Editor, Corchado, Emilio S., Advisory Editor, Hagras, Hani, Advisory Editor, Kóczy, László T., Advisory Editor, Kreinovich, Vladik, Advisory Editor, Lin, Chin-Teng, Advisory Editor, Lu, Jie, Advisory Editor, Melin, Patricia, Advisory Editor, Nedjah, Nadia, Advisory Editor, Nguyen, Ngoc Thanh, Advisory Editor, Wang, Jun, Advisory Editor, Bagnara, Sebastiano, editor, Tartaglia, Riccardo, editor, Albolino, Sara, editor, Alexander, Thomas, editor, and Fujita, Yushi, editor

Published
2019
Full Text
View/download PDF

3. Long-term Results of a Multicenter Randomized, Comparative Trial of Modified CHOP versus THP-COP versus THP-COPE Regimens in Elderly Patients with Non-Hodgkin’s Lymphoma

Author

Mori, Mayumi, Kitamura, Kiyoshi, Masuda, Michihiko, Hotta, Tomomitsu, Miyazaki, Tamotsu, Miura, Akira B., Mizoguchi, Hideaki, Shibata, Akira, Saito, Hidehiko, Matsuda, Tamotsu, Masaoka, Toru, Harada, Mine, Niho, Yoshiyuki, Takaku, Fumimaro, and The Japanese Clinical Study Group of THP Lymphomas in the Elderly (JGTLE)

Published
2005
Full Text
View/download PDF

16. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study

Author

Usuki, Kensuke, Urabe, Akio, Masaoka, Toru, Ohno, Ryuzo, Mizoguchi, Hideaki, Hamajima, Nobuyuki, Miyazaki, Tamotsu, Niitsu, Yousirou, Yoshida, Yutaka, Miura, Akira, Shibata, Akira, Abe, Tsukasa, Miura, Yasusada, Ikeda, Yasuo, Nomura, Takeo, Nagao, Tadami, Saitou, Hidehiko, Shirakawa, Shigeru, Ohkuma, Minoru, Matsuda, Tamotsu, Nakamura, Toru, Horiuchi, Atsushi, Kuramoto, Atsushi, Kimura, Ikurou, Irino, Syozo, Niho, Yoshiyuki, Takatsuki, Kiyoshi, Tomonaga, Masao, Uchino, Haruto, and Takaku, Fumimaro

Published
2002

39. Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients

Author

Myou, Shigeharu, Fujimura, Masaki, Nishi, Kohichi, Ohka, Takio, and Matsuda, Tamotsu

Subjects
Enzyme inhibitors -- Physiological aspects, Acetaldehyde -- Physiological aspects, Asthma -- Physiological aspects, Health, Physiological aspects
Abstract

We recently reported that inhaled acetaldehyde causes bronchoconstriction indirectly via histamine release in patients with asthma. The purpose of this study was to investigate a role of thromboxane [A.sub.2] in [...]

Published
1994

40. Transient wheeze: eosinophilic bronchobronchiolitis in acute eosinophilic pneumonia

Author

Ogawa, Haruhiko, Fujimura, Masaki, Matsuda, Tamotsu, Nakamura, Hiroyuki, Kumabashiri, Ichiro, and Kitagawa, Shunsuke

Subjects
Eosinophil disorders -- Physiological aspects, Bronchiolitis -- Physiological aspects, Wheeze -- Causes of -- Physiological aspects, Health, Physiological aspects, Causes of
Abstract

The clinicopathologic features of five patients with acute eosinophilic pneumonia who presented with transient wheeze as well as acute onset of high fever, severe hypoxemia, and diffuse pulmonary infiltrates arc [...]

Published
1993

41. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines

Author

Kasahara, Kazuo, Fujiwara, Yasuhiro, Sugimoto, Yoshikazu, Nishio, Kazuto, Tamura, Tomohide, Matsuda, Tamotsu, and Saijo, Nagahiro

Subjects
DNA topoisomerase II -- Physiological aspects, Doxorubicin -- Evaluation, Etoposide -- Evaluation, Cell lines -- Physiological aspects, Lung cancer -- Drug therapy, Health
Abstract

Background: Small-cell lung cancer (SCLC) is more sensitive to anticancer agents than non-small-cell lung cancer (NSCLC), but few studies have analyzed the mechanisms of natural drug resistance responsible for this difference. Purpose: To elucidate these mechanisms, we determined drug sensitivity and evaluated the biochemical parameters affecting response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in both types of cancer cell lines, in particular the activity and content of DNA topoisomerase, II, as well as etoposide uptake and cell doubling time. Methods: Drug sensitivy and cellular uptake of etoposide were determined by clonegenic assay and accumulation of radiolabeled drug, respectively. The topoisomerase II activity was assayed by decatenation of kinetoplast DNA to minicircle DNA using nuclear protein, and the content was determined by immunoblot analysis of nuclear extracts. We also compared the topoisomerase II content in parent cell lines with that in lines with cisplatin resistance acquired in vitro. Results: Sensitivities to doxorubicin and etoposide were higher in SCLC cell lines than in NSCLC lines, and the difference was statistically significant. Etoposide uptake in SCLC cells was higher than in NSCLC cells; the difference was statistically significant, but this difference may not be sufficient to account for the variation in sensitivities of the cell lines. Topoisomerase II activities of nuclear protein from SCLC cell lines were reproducibly twofold higher than those for NSCLC cell lines. The topoisomerase II content in nuclear protein appeared to be higher in SCLC cell lines than in NSCLC cell lines and corresponded to the sensitivities to doxorubicin and etoposide. In the cisplatin-resistant NSCLC cell lines PC-7/CDDP and PC-14/CDDP, the topoisomerase II content was increased compared with that in the parent lines, but the topoisomerase II content in other cisplatin-sensitive parent lines was similar to that in resistant sublines. Conclusions: These findings suggest that the topoisomerase II activity and content may be major factors in determining sensitivity to topoisomerase II inhibitors. [J Natl Cancer Inst 84:13-118,1992]

Published
1992

42. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma

Author

Yoshida, Takashi, Nakamura, Shinobu, Ohtake, Shigeki, Okafuji, Kazuhiro, Kobayashi, Kazumi, Kondo, Kunio, Kanno, Masatoshi, Matano, Sadaya, Matsuda, Tamotsu, Kanai, Masanobu, Sugimoto, Rippou, Ogawa, Makoto, and Takaku, Fumimaro

Subjects
Colony-stimulating factors (Physiology) -- Health aspects, Chemotherapy -- Adverse and side effects, Bone marrow, Health
Abstract

Most anticancer agents are nonspecific in their action against cells, and can cause myelosuppression, the inhibition of bone marrow function. Myelosuppression contributes to the development of infection, disease, and death, and causes a need to reduce doses of anticancer agents in cancer patients. Doses of anticancer agents are often limited by the development of neutropenia, a decrease in the number of neutrophils, a type of white blood cell. At the same time, effective treatment of cancer often requires large doses of anticancer drugs. One approach to preventing myelosuppression is bone marrow transplantation to accelerate recovery of bone marrow cells. Colony-stimulating factors enhance the growth of granulocytes, a granular type of white blood cell, and macrophages, a type of immune system defense cell. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was shown to stimulate the growth and development of neutrophils in monkeys experimentally treated with the anticancer drug cyclophosphamide and radiation. The effectiveness of rhG-CSF in stimulating the growth of bone marrow cells was assessed in 16 patients with non-Hodgkin's lymphoma, a cancer of the lymphatic system. These patients were receiving treatment with anticancer drugs that cause myelosuppression. The patients were treated with varying doses of rhG-CSF given by intravenous infusion for 14 days, starting three days after chemotherapy. The rhG-CSF was rapidly removed from the blood, and 50 percent of the given dose was eliminated by six hours. A dose of 100 micrograms (ug) of rhG-CSF per square meter (m) of body area per day decreased the duration of neutropenia and fever. The rhG-CSF was well tolerated and caused only slight bone pain. These findings suggest that the most effective dose of rhG-CSF in reducing myelosuppression caused by chemotherapy is 100 to 200 ug per square m per day. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

43. Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma

Author

Fujimura, Masaki, Sakamoto, Sayuri, and Matsuda, Tamotsu

Subjects
Bronchiectasis -- Physiological aspects -- Drug therapy, Asthma -- Drug therapy -- Physiological aspects, Health, Drug therapy, Physiological aspects
Abstract

One of the major clinical features of bronchial asthma is the increased bronchial responsiveness to various specific and nonspecific stimuli. (1) Thromboxane A[.sub.2] (TXA[.sub.2]), a metabolite of arachidonic acid, is [...]

Published
1990

44. Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects

Author

Fujimura, Masaki, Nishioka, Shinji, Kumabashiri, Ichiro, Matsuda, Tamotsu, and Mifune, Junichiro

Subjects
Bronchial spasm -- Physiological aspects -- Diagnosis, Acetylcholine -- Physiological aspects, Aerosol therapy -- Evaluation -- Physiological aspects, Asthma -- Diagnosis, Health, Diagnosis, Evaluation, Physiological aspects
Abstract

Bronchial hyperresponsiveness is one of the major clinical features of bronchial asthma. We previously reported that oral administration of a selective thromboxane synthetase inhibitor, OKY-046, reduced bronchial hyperresponsiveness to acetylcholine [...]

Published
1990

50. Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation

Author

Nakao, Shinji, primary, Zeng, Weihua, additional, Yamazaki, Hirohito, additional, Wang, Honbo, additional, Takami, Akiyoshi, additional, Sugimori, Naomi, additional, Miura, Yuji, additional, Shiobara, Shintaro, additional, Matsuda, Tamotsu, additional, Shinagawa, Yuji, additional, and Harada, Mine, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results